CHARLOTTESVILLE, Virginia and ATHENS, Greeece, December 1 /PRNewswire/ — Biovista Inc. today announced the signing of a new collaboration agreement with the Thalassaemia International Federation (TIF) for the installation and support of its JAnaemia patient record management system. JAnaemia, which has been customized, in this case for beta thalassaemia patients, will be initially installed at … Read More
Author: Vassilis Virvilis
BioWorld: Strong at the Broken Places: Models for Industry’s Future
By Trista Morrison, BioWorld Insight BioVista: Artificial Intelligence for Discovery What happens when you combine the vision of Anadys Pharmaceuticals Inc…You get BioVista Inc., a start-up with a drug profiling platform that goes way beyond data mining to identify new uses for existing compounds…BioVista also has generated an internal pipeline comprising more than 30 repurposed … Read More
Biovista to present at the Life Sciences and Healthcare Venture Summit
Charlottesville, Oct 10, 2009/ Biovista announced today that its President Dr. Aris Persidis will present at the Life Sciences and Healthcare Venture Summit being held on October 27th, at NYC. Dr. Persidis will discuss Biovista’s repositioning program including BVA-201 for MS and BVA-601 for epilepsy. He will also provide an overview of Biovista’s business model and … Read More
Biovista announces positive efficacy results in a pre-clinical trial of BVA-201 for Multiple Sclerosis
CHARLOTTESVILLE, Virginia, September 9 /PRNewswire/ — Biovista Inc. today announced that BVA-201, its drug targeting Multiple Sclerosis (MS), has shown significant positive results in the MOG-induced Experimental Allergic Encephalomyelitis (EAE) murine model of MS. BVA-201 is an existing drug that Biovista repositioned in MS and is aimed at neuroprotection. It was shown to have both … Read More
Biovista Inc. to present at upcoming CHI drug repositioning summit
Charlottesville, VA (9 September 2009): Biovista Inc. announced today that it will present at the CHI Drug Repositioning Summit in Boston, MA, Oct. 13-14, 2009. The presentation will highlight the efficiencies of repositioning as a development strategy, and introduce Biovista’s proprietary platform for repositioning and adverse event profiling. BVA-101, 201 and 601 will be presented as … Read More